Aktis Oncology, a biotechnology company specializing in solid tumors, has applied for a U.S. IPO with plans to raise $100 million.

Focused on the development of targeted radioactive drugs for solid tumors, Aktis Oncology (AKTS.US), a clinical stage biotechnology company, submitted an application to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise up to $100 million through an initial public offering (IPO). Aktis Oncology is a clinical stage oncology company with a core focus on alpha particle-emitting radioactive drugs for the treatment of common solid tumors. In its pipeline, Ac-AKY-1189, targeting cancers expressing the Nectin-4 protein, is currently undergoing a multicenter Phase Ib clinical trial in the United States, with approximately 150 enrolled patients. Preliminary clinical data is expected to be released in the first quarter of 2027. Another candidate drug, Ac-AKY-2519, targeting tumors expressing the B7-H3 protein, plans to submit an Investigational New Drug (IND) application in 2026. In addition, the company has established collaborations with multiple domestic and international institutions for isotope supply and is planning to start operating its internally cGMP compliant manufacturing facility in 2026. The company is also conducting collaborative research to expand its portfolio of targeted radioactive conjugate drug projects. Founded in 2020 and headquartered in Boston, Massachusetts, the company generated $6 million in revenue in the 12 months ending on September 30, 2025. The company plans to list on the NASDAQ under the ticker symbol AKTS. The joint book-running managers for this IPO include J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen, and specific pricing terms have not been disclosed.